公告日期：2026-03-28

Walvax Biotechnology 2025 Sustainability Report Message from the Chairman

Walvax Biotechnology 2025 Sustainability Report About Walvax Biotechnology
About Walvax Biotechnology
Company Profile

In the human vaccines segment, the Company continues to deepen its international expansion

and advance the development of multivalent combination vaccines, ensuring that technological

Walvax Biotechnology Co., Ltd. (hereinafter referred to as diseases, and HPV (human papillomavirus). Building on its estab- innovation is aligned with market needs.

“Walvax Biotechnology”) was founded in 2001 and listed on lished capabilities in biopharmaceutical innovation and indus- Human Vaccines

the Shenzhen Stock Exchange in 2010 (stock code: 300142), trialization, the Company continues to consolidate and expand

becoming the first enterprise from Yunnan Province to be listed its leading position in human vaccines, while actively extending

on China’s ChiNext board. Walvax Biotechnology consistently into emerging fields such as sy……
[点击查看PDF原文]

提示：本网不保证其真实性和客观性，一切有关该股的有效信息，以交易所的公告为准，敬请投资者注意风险。